Equities

Transcenta Holding Ltd

Transcenta Holding Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.04
  • Today's Change0.04 / 4.00%
  • Shares traded143.00k
  • 1 Year change-73.87%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5468951,222
Total Receivables, Net475287
Total Inventory182121
Prepaid expenses112329
Other current assets, total626637
Total current assets6841,0561,396
Property, plant & equipment, net439457485
Goodwill, net472472472
Intangibles, net969696
Long term investments1.265124
Note receivable - long term0.501.7166
Other long term assets------
Total assets1,6932,1352,545
LIABILITIES
Accounts payable924831
Accrued expenses568161
Notes payable/short-term debt000
Current portion long-term debt/capital leases382393280
Other current liabilities, total242854
Total current liabilities554550426
Total long term debt281985
Total debt410411365
Deferred income tax252526
Minority interest----0
Other liabilities, total586643
Total liabilities666661579
SHAREHOLDERS EQUITY
Common stock0.280.270.29
Additional paid-in capital4,6584,6664,757
Retained earnings (accumulated deficit)(3621)(3186)(2796)
Treasury stock - common(0.02)(0.01)(0.01)
Unrealized gain (loss)------
Other equity, total(8.96)(5.86)5.09
Total equity1,0281,4741,966
Total liabilities & shareholders' equity1,6932,1352,545
Total common shares outstanding406420445
Treasury shares - common primary issue3000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.